FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1479370285> ?p ?o ?g. }

• W1479370285 endingPage "5751" @default.
• W1479370285 startingPage "5751" @default.
• W1479370285 abstract "Upregulation of vascular endothelial growth factor (VEGF) expression can inhibit intimal thickening after vascular injury. However, the lack of efficient gene delivery systems leads to insufficient VEGF expression, which prevents its application in gene therapy. In the present study, to improve the delivery of the plasmid vector with the VEGF gene (pVEGF165) to the injured vessel wall, we explored the potentially important difference between endothelial cell-targeted and nontargeted polymeric carriers. The αvβ3 integrin is overexpressed on activated endothelial cells but not on normal quiescent vessels. In this study, CDG2-cRGD, synthesized by conjugating an αvβ3 integrin-binding cyclic arginylglycylaspartic acid (cRGD) peptide with the Generation 2 polycation polyamidoamine (PAMAMG2)-g-cyclodextrin (termed as CDG2), was developed as a targetable carrier. It was observed that the specific integrin-ligand interactions greatly enhanced cellular internalization of CDG2-cRGD in human umbilical vein endothelial cells (HUVECs), which are notoriously difficult to transfect. Consequently, HUVECs were found to show remarkably high levels of VEGF165 expression induced by the CDG2-cRGD polyplex. Interestingly, VEGF165 overexpression in vivo was more complex than that in vitro, and in vivo assays demonstrated that the stimulus response to balloon injury in arteries could obviously upregulate VEGF165 expression in the saline-treated group, although it was not enough to prevent intimal thickening. In gene-transfected groups, intravascular delivery of pVEGF165 with the CDG2-cRGD polyplex into rabbits after vascular injury resulted in a significant inhibition of intimal thickening at 4 weeks, whereas the low therapeutic efficacy in the nontargeted CDG2-treated group was only comparable to that in the saline-treated group. It is becoming clear that the conflicting results of VEGF165 gene therapy in two gene-transfected groups are reflective of the pivotal role of the cRGD-conjugated carriers in achieving the beneficial therapeutic effects of vascular gene therapy." @default.
• W1479370285 created "2016-06-24" @default.
• W1479370285 creator A5006769166 @default.
• W1479370285 creator A5013495945 @default.
• W1479370285 creator A5021047011 @default.
• W1479370285 creator A5067654301 @default.
• W1479370285 creator A5076816766 @default.
• W1479370285 creator A5077108198 @default.
• W1479370285 creator A5078936529 @default.
• W1479370285 date "2015-09-01" @default.
• W1479370285 modified "2023-09-25" @default.
• W1479370285 title "Endothelial cell-targeted pVEGF165 polyplex plays a pivotal role in inhibiting intimal thickening after vascular injury" @default.
• W1479370285 cites W1965772932 @default.
• W1479370285 cites W1982428215 @default.
• W1479370285 cites W1986842655 @default.
• W1479370285 cites W1993162834 @default.
• W1479370285 cites W2008647957 @default.
• W1479370285 cites W2010731545 @default.
• W1479370285 cites W2013841789 @default.
• W1479370285 cites W2015920239 @default.
• W1479370285 cites W2021043619 @default.
• W1479370285 cites W2023329601 @default.
• W1479370285 cites W2024288824 @default.
• W1479370285 cites W2026250154 @default.
• W1479370285 cites W2035582199 @default.
• W1479370285 cites W2039310374 @default.
• W1479370285 cites W2039551908 @default.
• W1479370285 cites W2043069157 @default.
• W1479370285 cites W2048220093 @default.
• W1479370285 cites W2048598450 @default.
• W1479370285 cites W2054213917 @default.
• W1479370285 cites W2055499605 @default.
• W1479370285 cites W2058017574 @default.
• W1479370285 cites W2072238545 @default.
• W1479370285 cites W2074133546 @default.
• W1479370285 cites W2074870430 @default.
• W1479370285 cites W2076079209 @default.
• W1479370285 cites W2081866761 @default.
• W1479370285 cites W2086360593 @default.
• W1479370285 cites W2086439640 @default.
• W1479370285 cites W2086731246 @default.
• W1479370285 cites W2092045871 @default.
• W1479370285 cites W2099354378 @default.
• W1479370285 cites W2102951302 @default.
• W1479370285 cites W2106048944 @default.
• W1479370285 cites W2112911107 @default.
• W1479370285 cites W2129144690 @default.
• W1479370285 cites W2156969927 @default.
• W1479370285 cites W2163371839 @default.
• W1479370285 cites W2312929927 @default.
• W1479370285 cites W2313378998 @default.
• W1479370285 cites W2314913625 @default.
• W1479370285 cites W60021579 @default.
• W1479370285 doi "https://doi.org/10.2147/ijn.s88109" @default.
• W1479370285 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4583553" @default.
• W1479370285 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26425083" @default.
• W1479370285 hasPublicationYear "2015" @default.
• W1479370285 type Work @default.
• W1479370285 sameAs 1479370285 @default.
• W1479370285 citedByCount "5" @default.
• W1479370285 countsByYear W14793702852019 @default.
• W1479370285 countsByYear W14793702852020 @default.
• W1479370285 countsByYear W14793702852021 @default.
• W1479370285 countsByYear W14793702852022 @default.
• W1479370285 countsByYear W14793702852023 @default.
• W1479370285 crossrefType "journal-article" @default.
• W1479370285 hasAuthorship W1479370285A5006769166 @default.
• W1479370285 hasAuthorship W1479370285A5013495945 @default.
• W1479370285 hasAuthorship W1479370285A5021047011 @default.
• W1479370285 hasAuthorship W1479370285A5067654301 @default.
• W1479370285 hasAuthorship W1479370285A5076816766 @default.
• W1479370285 hasAuthorship W1479370285A5077108198 @default.
• W1479370285 hasAuthorship W1479370285A5078936529 @default.
• W1479370285 hasBestOaLocation W14793702851 @default.
• W1479370285 hasConcept C104317684 @default.
• W1479370285 hasConcept C111599444 @default.
• W1479370285 hasConcept C123012128 @default.
• W1479370285 hasConcept C127561419 @default.
• W1479370285 hasConcept C135983454 @default.
• W1479370285 hasConcept C139770010 @default.
• W1479370285 hasConcept C1491633281 @default.
• W1479370285 hasConcept C150903083 @default.
• W1479370285 hasConcept C185592680 @default.
• W1479370285 hasConcept C202751555 @default.
• W1479370285 hasConcept C203014093 @default.
• W1479370285 hasConcept C207001950 @default.
• W1479370285 hasConcept C2777411675 @default.
• W1479370285 hasConcept C502942594 @default.
• W1479370285 hasConcept C54009773 @default.
• W1479370285 hasConcept C55493867 @default.
• W1479370285 hasConcept C71924100 @default.
• W1479370285 hasConcept C86803240 @default.
• W1479370285 hasConcept C95444343 @default.
• W1479370285 hasConceptScore W1479370285C104317684 @default.
• W1479370285 hasConceptScore W1479370285C111599444 @default.
• W1479370285 hasConceptScore W1479370285C123012128 @default.
• W1479370285 hasConceptScore W1479370285C127561419 @default.
• W1479370285 hasConceptScore W1479370285C135983454 @default.

• next